SBT-101
| CAS No. | SBT-101 | Cat. No. | BCP49363 |
| Name | SBT-101 | ||
| Synonyms | SBT101;SBT 101; | ||
| Formula | M. Wt | ||
| Description | SBT101 is the first AAV-based gene therapy in development designed to compensate for the disease-causing ABCD1 mutation, to increase ABCD1 expression, and reduce very long chain fatty acid (VLCFA) levels specifically for people living with adrenomyeloneuropathy (AMN). | ||
| Pathways | Jak/Stat Pathway Others Pathway | ||
| Targets | Others Stat | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.